Research Article

You have full text access to this OnlineOpen article

Glucosamine sulfate in the treatment of knee osteoarthritis symptoms: A randomized, double-blind, placebo-controlled study using acetaminophen as a side comparator†

  1. Gabriel Herrero-Beaumont1,‡,*,
  2. José Andrés Román Ivorra2,
  3. María del Carmen Trabado3,
  4. Francisco Javier Blanco4,
  5. Pere Benito5,
  6. Emilio Martín-Mola6,
  7. Javier Paulino7,
  8. José Luis Marenco8,
  9. Armando Porto9,
  10. Armando Laffon10,
  11. Domingos Araújo11,
  12. Manuel Figueroa12,
  13. Jaime Branco13

Article first published online: 30 JAN 2007

DOI: 10.1002/art.22371

Issue

Arthritis & Rheumatism

Arthritis & Rheumatism

Volume 56, Issue 2, pages 555–567, February 2007

Additional Information

How to Cite

Herrero-Beaumont, G., Ivorra, J. A. R., del Carmen Trabado, M., Blanco, F. J., Benito, P., Martín-Mola, E., Paulino, J., Marenco, J. L., Porto, A., Laffon, A., Araújo, D., Figueroa, M. and Branco, J. (2007), Glucosamine sulfate in the treatment of knee osteoarthritis symptoms: A randomized, double-blind, placebo-controlled study using acetaminophen as a side comparator. Arthritis & Rheumatism, 56: 555–567. doi: 10.1002/art.22371

Author Information

  1. 1

    Fundación Jiménez Díaz-Capio, Madrid, Spain

  2. 2

    Hospital Dr. Peset, Valencia, Spain

  3. 3

    Hospital Clinic, Barcelona, Spain

  4. 4

    Hospital Universitario Juan Canalejo, A Coruña, Spain

  5. 5

    Hospital del Mar, Barcelona, Spain

  6. 6

    Hospital Universitario La Paz, Madrid, Spain

  7. 7

    Completo Hospitalario De Ciudad Real, Ciudad Real, Spain

  8. 8

    Hospital Nuestra Señora De Valme, Seville, Spain

  9. 9

    Hospital Universitario Coimbra, Portugal

  10. 10

    Hospital De La Princesa, Madrid, Spain

  11. 11

    Hospital Conde de Bertiandos, Ponte de Lima, Portugal

  12. 12

    Hospital Donostia, San Sebastian, Spain

  13. 13

    Centro Hospitalar de Lisboa Occidental, EPE/Hospital Egas Moniz, Lisbon, Portugal

  1. ‡

    Dr. Herrero-Beaumont has received speaking fees (less than $10,000) from Rottapharm.

*Rheumatology Department, Fundación Jiménez Díaz-Capio, Autonomous University of Madrid, Avenida Reyes Catolicos 2, 28040 Madrid, Spain

  1. †

    ClinicalTrials.gov identifier: NCT00110474.

Publication History

  1. Issue published online: 30 JAN 2007
  2. Article first published online: 30 JAN 2007
  3. Manuscript Accepted: 23 OCT 2006
  4. Manuscript Received: 16 MAY 2006

Funded by

  • Rottapharm

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (135K)

REFERENCES

  • 1
    Felson DT, Lawrence RC, Hochberg MC, McAlindon T, Dieppe PA, Minor MA, et al. Osteoarthritis: new insights. Part 2. Treatment approaches. Ann Intern Med 2000; 133: 726–37.
  • 2
    American College of Rheumatology Subcommittee on Osteoarthritis Guidelines. Recommendations for the medical management of osteoarthritis of the hip and knee: 2000 update. Arthritis Rheum 2000; 43; 1905–15.
    Direct Link:
  • 3
    Jordan KM, Arden NK, Doherty M, Bannwarth B, Bijlsma JW, Dieppe P, et al. EULAR recommendations 2003: an evidence based approach to the management of knee osteoarthritis: report of a task force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT). Ann Rheum Dis 2003; 62: 1145–55.
  • 4
    Reginster JY, Deroisy R, Rovati LC, Lee RL, Lejeune E, Bruyere O, et al. Long-term effects of glucosamine sulfate on osteoarthritis progression: a randomised, placebo-controlled clinical trial. Lancet 2001; 357: 251–6.
  • 5
    Pavelka K, Gatterova J, Olejarova M, Machacek S, Giacovelli G, Rovati LC. Glucosamine sulfate use and delay of progression of knee osteoarthritis: a 3-year, randomized, placebo-controlled, double-blind study. Arch Intern Med 2002; 162: 2113–23.
  • 6
    Russell AS, Aghazadeh-Habashi A, Jamali F. Active ingredient consistency of commercially available glucosamine sulfate products. J Rheumatol 2002; 29: 2407–9.
  • 7
    McAlindon T, Formica M, LaValley M, Lehmer M, Kabbara K. Effectiveness of glucosamine for symptoms of knee osteoarthritis: results from an internet-based randomized double-blind controlled trial. Am J Med 2004; 117: 643–9.
  • 8
    Cibere J, Kopec JA, Thorne A, Singer J, Canvin J, Robinson DB, et al. Randomized, double-blind, placebo-controlled glucosamine discontinuation trial in knee osteoarthritis. Arthritis Care Res 2004; 51: 738–45.
    Direct Link:
  • 9
    Towheed TE, Maxwell L, Anastassiades TP, Shea B, Houpt J, Robinson V, et al. Glucosamine therapy for treating osteoarthritis. Cochrane Database Syst Rev [serial online]. 2005; (2):CD002946. URL: http://www.thecochranelibrary.com.
  • 10
    McAlindon T. Why are clinical trials of glucosamine no longer uniformly positive? Rheum Dis Clin N Am 2003; 29: 789–801.
  • 11
    Clegg DO, Reda DJ, Harris CL, Klein MA, for the GAIT Investigators. The efficacy of glucosamine and chondroitin sulfate in patients with painful knee osteoarthritis (OA): the Glucosamine/chondroitin Arthritis Intervention Trial [abstract]. Arthritis Rheum 2005; 52 Suppl 9: S256.
  • 12
    Herrero-Beaumont G, Roman JA, Trabado MC, Blanco FJ, Benito P, Martin-Mola E, et al. Effects of glucosamine sulfate on 6-month control of knee osteoarthritis symptoms versus placebo and acetaminophen: results from the Glucosamine Unum In Die Efficacy (GUIDE) trial [abstract]. Arthritis Rheum 2005; 52 Suppl 9: S460.
  • 13
    Clegg DO, Reda DJ, Harris CL, Klein MA, O'Dell JR, Hooper MM, et al. Glucosamine, chondroitin sulfate and the two in combination for painful knee osteoarthritis. N Engl J Med 2006; 354: 795–808.
  • 14
    Altman R, Asch E, Bloch D, Bole G, Borenstein D, Brandt K, et al. Development of criteria for the classification and reporting of osteoarthritis: classification of osteoarthritis of the knee. Arthritis Rheum 1986; 29: 1039–49.
    Direct Link:
  • 15
    Altman R, Brandt K, Hochberg M, Moskowitz R. Design and conduct of clinical trials of patients with osteoarthritis: recommendations from a task force of the Osteoarthritis Research Society. Osteoarthritis Cartilage 1996; 4: 217–43.
  • 16
    Kellgren JH, Lawrence JS. Radiological assessment of osteoarthrosis. Ann Rheum Dis 1957; 16: 494–501.
  • 17
    Lequesne MG, Mery C, Samson M, Gerard P. Indexes of severity for osteoarthritis of the hip and knee: validation-value in comparison with other assessment tests. Scand J Rheumatol Suppl 1987; 65: 85–9.
  • 18
    Bellamy N, Buchanan WW, Goldsmith CH, Campbell J, Stitt LW. Validation of WOMAC: a health status instrument for measuring clinically important patient relevant outcomes to antirheumatic drug therapy in patients with osteoarthritis of the hip or knee. J Rheumatol 1988; 15: 1833–40.
  • 19
    Dougados M, LeClaire P, van der Heijde D, Bloch DA, Bellamy N, Altman RD. A report of the Osteoarthritis Research Society International standing committee for clinical trials response criteria initiative. Osteoarthritis Cartilage 2000; 8: 395–403.
  • 20
    Tubach F, Ravaud P, Baron G, Falissard B, Logeart I, Bellamy N, et al. Evaluation of clinically relevant changes in patient reported outcomes in knee and hip osteoarthritis: the minimal clinically important improvement. Ann Rheum Dis 2005; 64: 29–33 [originally published online 18 June 2004].
  • 21
    Tubach F, Ravaud P, Baron G, Falissard B, Logeart I, Bellamy N, et al. Evaluation of clinically relevant states in patient reported outcomes in knee and hip osteoarthritis: the patient acceptable symptom state. Ann Rheum Dis 2005; 64: 34–7 [originally published online 6 May 2004].
  • 22
    Noack W, Fischer M, Forster KK, Rovati LC, Setnikar I. Glucosamine sulfate in osteoarthritis of the knee. Osteoarthritis Cartilage 1994; 2: 51–9.
  • 23
    Pocock SJ. Clinical trials: a practical approach. Chichester (UK): John Wiley & Sons; 1983. p. 123–41.
  • 24
    Hedges LV, Olkin I. Statistical methods for meta-analysis. Orlando (FL): Academic Press; 1985.
  • 25
    Proschan MA, Waclawiw MA. Practical guidelines for multiplicity adjustment in clinical trials. Control Clin Trials 2000; 21: 527–39.
  • 26
    Hochberg Y, Benjamini Y. More powerful procedures for multiple significance testing. Stat Med 1990; 9: 811–8.
    Direct Link:
  • 27
    Committee for Proprietary Medicinal Products. Points to consider on clinical investigation of medicinal products used in the treatment of osteoarthritis (CPMP/EWP/784/97). London: European Agency for the Evaluation of Medicinal Products; 1998.
  • 28
    Towheed TE, Maxwell L, Judd MG, Catton M, Hochberg MC, Wells G. Acetaminophen for osteoarthritis. Cochrane Database Syst Rev 2006; (1):CD004257. URL: http://www.thecochranelibrary.com.
  • 29
    Garcia Rodriguez LA, Hernandez-Diaz S. The risk of upper gastrointestinal complications associated with nonsteroidal anti-inflammatory drugs, glucocorticoids, acetaminophen and combination of these agents. Arthritis Res 2001; 3: 98–101.
  • 30
    Kazis LE, Anderson JJ, Meenan RF. Effect sizes for interpreting changes in health status. Med Care 1989; 27 Suppl 3: S178–89.
  • 31
    Bjordal JM, Ljunggren AE, Klovning A, Slordal L. Non-steroidal anti-inflammatory drugs, including cyclo-oxygenase-2 inhibitors, in osteoarthritis knee pain: meta-analysis of randomised placebo controlled trials. BMJ 2004; 329: 1317–22.
  • 32
    Hochberg MC. Nutritional supplements for knee osteoarthritis—still no resolution [editorial]. N Engl J Med 2006; 354: 858–60.
  • 33
    Houpt JB, McMillan R, Wein C, Paget-Dellio SD. Effect of glucosamine hydrochloride in the treatment of pain of osteoarthritis of the knee. J Rheumatol 1999; 26: 2423–30.
  • 34
    Persiani S, Roda E, Rovati LC, Locatelli M, Giacovelli G, Roda A. Glucosamine oral bioavailability and plasma pharmacokinetics after increasing doses of crystalline glucosamine sulfate in man. Ostoeoarthritis Cartilage 2005; 13: 1041–9.
  • 35
    Persiani S, Rotini R, Trisolino G, Delliponti L, Rovati LC, Locatelli M, et al. Glucosamine plasma and synovial fluid concentrations before and after oral administration of crystalline glucosamine sulfate in knee osteoarthritis patients [abstract]. Arthritis Rheum 2005; 52 Suppl 9: S508.
  • 36
    Biggee BA, Blinn CM, McAlindon TE, Nuite M, Silbert JE. Low levels of human serum glucosamine after ingestion of glucosamine sulfate relative to capability for peripheral effectiveness. Ann Rheum Dis 2006; 65: 222–6.
  • 37
    Piepoli T, Zanelli T, Letari O, Persiani S, Rovati LC, Caselli G. Glucosamine sulfate inhibits IL-1-stimulated gene expression at concentrations found in humans after oral intake [abstract]. Arthritis Rheum 2005; 52 Suppl 9: S502.
  • 38
    Largo R, Alvarez-Soria MA, Diez-Ortego I, Calvo E, Sanchez-Pernaute O, Egido J, et al. Glucosamine inhibits IL-1β-induced NFκB activation in human osteoarthritic chondrocytes. Osteoarthritis Cartilage 2003; 11: 290–8.
  • 39
    Jackson CG, Plaas AH, Barnhill JG, Harris CL, Clegg DO. The pharmacokinetics of oral glucosamine and chondroitin sulfate in humans [abstract]. Arthritis Rheum 2005; 52: 4062–3.
  • 40
    Blinn CM, Dibbs ER, Hronowski LJ, Vokonas PS, Silbert JE. Fasting serum sulfate levels before and after development of osteoarthritis in participants of the Veterans Administration Normative Aging Longitudinal Study do not differ from levels in participants in whom osteoarthritis did not develop. Arthritis Rheum 2005; 52: 2808–13.
    Direct Link:
  • 41
    Hoffer LJ, Kaplan LN, Hamadeh MJ, Grigoriu AC, Baron M. Sulfate could mediate the therapeutic effect of glucosamine sulfate. Metabolism 2001; 50: 767–70.
  • 42
    Cordoba F, Nimni ME. Chondroitin sulfate and other sulfate containing chondroprotective agents may exhibit their effects by overcoming a deficiency of sulfur amino acids. Osteoarthritis Cartilage 2003; 11: 228–30.
  • 43
    Lequesne M, Brandt K, Bellamy N, Moskowitz R, Menkes CJ, Pelletier JP, et al. Guidelines for testing slow acting drugs in osteoarthritis. J Rheumatol Suppl 1994; 41: 65–71.
  • 44
    Bruyere O, Reginster JY, Giacovelli G, Barbetta B, Rovati LC, Pavelka K. Clinical significance of the long-term symptom-modifying effects of glucosamine sulfate: comment on the article by Brandt and Mazzuca [letter]. Arthritis Rheum 2006; 54: 2339–41.
    Direct Link:
  • 45
    McAlindon TE, LaValley MP, Gulin JP, Felson DT. Glucosamine and chondroitin for treatment of osteoarthritis: a systematic quality assessment and meta-analysis. JAMA 2000; 283: 1469–75.
  • 46
    Richy F, Bruyere O, Ethgen O, Cucherat M, Henrotin Y, Reginster JY. Structural and symptomatic efficacy of glucosamine and chondroitin in knee osteoarthritis: a comprehensive meta-analysis. Arch Intern Med 2003; 163: 1514–22.
  • 47
    Williams HJ, Ward JR, Egger MJ, Neuner R, Brooks RH, Clegg DO, et al. Comparison of naproxen and acetaminophen in a two-year study of treatment of osteoarthritis of the knee. Arthritis Rheum 1993; 36: 1196–206.
    Direct Link:
  • 48
    Temple RA, Benson GD, Zinsenheim JR, Schweinle JE. Multicenter, randomized, double-blind, active-controlled, parallel-group trial of the long-term (6–12 months) safety of acetaminophen in adult patients with osteoarthritis. Clin Ther 2006; 28: 222–35.
  • 49
    McAlindon T. Glucosamine for osteoarthritis: dawn of a new era? Lancet 2001; 357: 247–8.
View Full Article (HTML) Get PDF (135K)